Magazine Article | August 3, 2020

Companies To Watch: Cidara Therapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Training its novel treatment and preventative for flu and other viral infections on COVID-19

SNAPSHOT

Cidara Therapeutics’ lead drug, rezafungin, now in Phase 3 development, is a broad-spectrum antifungal in a known class, the echinocandins, but the COVID-19 pandemic has moved the spotlight to the antiviral Fc-conjugate (AVC) drugs in the company’s novel antiviral platform that offer both prevention and treatment. Its AVCs are designed to attack viruses directly and also activate the immune system against them. In Cidara’s pipeline, the lead antiviral drug, coded CD377, targets influenza, but other potential targets are RSV (respiratory syncytial virus), HIV, and COVID-19.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader